Loading...
You are viewing a DELETED record.
This record information is displayed for reference purpose only and should be not used.
This document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
ALVAC‐HIV Vaccine
EN
vCP1521
No
-
PA,Person:D.L. SkeaDeputy director Regulatory Affair,
, United States of AmericaPhone: 4166672701,Fax:Email: Danna.Skea@sanofipasteur.com,Website:Related OrganizationSanofi Pasteur ()Private sector (business and industry)PA,
, United States of AmericaPhone: 4166672701,Fax:Email: Danna.Skea@sanofipasteur.com,Website:
ALVAC‐HIV (vCP1521) vaccine is a modified Canarypox virus carrying three Human immunodeficiency virus 1 genes (gag, pol and env). After inoculation and entry into the host cell, the viral vector contains the necessary sequences to direct the transient expression of the HIV-1 proteins, which will be presented to the host immune system. Since the viral particle (and viral genome) cannot enter the nucleus, transcription and translation are restricted to the cytoplasm. Further, DNA integration and recombination with the host genome cannot also not occur. The modified virus is replication deficient in human cells and thus not expected to cause disease. However, the modified virus is expected to replicate in avian species and passive cell lines.
In addition to using a modified virus, some experimental dosing regimes have also included the use of a secondary protein subunit vaccine, AIDSVAX B/E, which is composed of recombinant gp120, an envelope protein on the surface of HIV.
EN
In addition to using a modified virus, some experimental dosing regimes have also included the use of a secondary protein subunit vaccine, AIDSVAX B/E, which is composed of recombinant gp120, an envelope protein on the surface of HIV.
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-45008-6 Organism Canarypox virus (CNPV)Viruses
The original strain of Canarypox virus (Rentschler strain) was attenuated by serial passages on chicken embryo fibroblasts. The attenuated virus was plaque isolated and designated as ALVAC.
EN
ALVAC
EN
- Other (Recombinant DNA)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-116144-1 Envelope glycoprotein gp160 | Human immunodeficiency virus 1 - HIV-1Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-116153-1 Gag polyprotein | Human immunodeficiency virus 1 - HIV-1Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-116155-1 Pol polyprotein | Human immunodeficiency virus 1 - HIV-1Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-103890-2 H6 Gene Promoter | Vaccinia virus (Poxvirus, Smallpox vaccine, VACV, VV, Vaccinia)Promoter
-
BCH-GENE-SCBD-116156-2 I3L promoter | Vaccinia virus (Poxvirus, Smallpox vaccine, VACV, VV, Vaccinia)Promoter
The HIV-1 gene sequences, which were inserted in the ALVAC vector, are:
• Envelope protein, consisting of the extracellular gp120 moiety of the ZM96 strain of HIV-1 linked to the transmembrane anchor gp41 from LAI strain of HIV-1. The env sequence is under the control of the Vaccinia virus H6 promoter.
• Gag polyprotein and Pol polyprotein, consisting of the gag gene encoding the entire Gag protein and a portion of the pol sequence sufficient to encode the protease function. The sequences were sourced from the LAI strain of HIV-1. The gag-pol gene sequences are under the control of the same Vaccinia virus I3L promoter.
EN
• Envelope protein, consisting of the extracellular gp120 moiety of the ZM96 strain of HIV-1 linked to the transmembrane anchor gp41 from LAI strain of HIV-1. The env sequence is under the control of the Vaccinia virus H6 promoter.
• Gag polyprotein and Pol polyprotein, consisting of the gag gene encoding the entire Gag protein and a portion of the pol sequence sufficient to encode the protease function. The sequences were sourced from the LAI strain of HIV-1. The gag-pol gene sequences are under the control of the same Vaccinia virus I3L promoter.
EN
- Vaccine
EN
EN
- ClinicalTrial.gov - HIV Candidate Vaccine, ALVAC-HIV-1 [ English ]
- A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells.pdf [ English ]
- Replication-Defective Canarypox (ALVAC) Vectors Effectively Activate Anti–Human Immunodeficiency Virus-1 Cytotoxic T Lymphocytes Present in Infected Patients - Implications for Antigen-Specific Immunotherapy.pdf [ English ]
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand.pdf [ English ]
| Record type | Field | Record(s) | |||||
|---|---|---|---|---|---|---|---|
|
|||||||
